ATE327258T1 - Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung - Google Patents

Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung

Info

Publication number
ATE327258T1
ATE327258T1 AT96906907T AT96906907T ATE327258T1 AT E327258 T1 ATE327258 T1 AT E327258T1 AT 96906907 T AT96906907 T AT 96906907T AT 96906907 T AT96906907 T AT 96906907T AT E327258 T1 ATE327258 T1 AT E327258T1
Authority
AT
Austria
Prior art keywords
monoclonal antibody
producing
reacting specifically
antibody reacting
fas ligand
Prior art date
Application number
AT96906907T
Other languages
English (en)
Inventor
Nobuhiko Kayagaki
Hideo Yagita
Ko Okumura
Motomi Nakata
Original Assignee
Ko Okumura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ko Okumura filed Critical Ko Okumura
Application granted granted Critical
Publication of ATE327258T1 publication Critical patent/ATE327258T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
AT96906907T 1995-03-20 1996-03-21 Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung ATE327258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8742095 1995-03-20
JP30349295 1995-10-27

Publications (1)

Publication Number Publication Date
ATE327258T1 true ATE327258T1 (de) 2006-06-15

Family

ID=26428696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906907T ATE327258T1 (de) 1995-03-20 1996-03-21 Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung

Country Status (8)

Country Link
US (1) US6946255B1 (de)
EP (1) EP0872488B1 (de)
JP (1) JP3451092B2 (de)
AT (1) ATE327258T1 (de)
AU (1) AU716731B2 (de)
CA (1) CA2215905A1 (de)
DE (1) DE69636170T2 (de)
WO (1) WO1996029350A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
AU724856B2 (en) * 1995-06-30 2000-10-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US6777540B1 (en) * 1996-09-02 2004-08-17 Ko Okumura Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
JP2002530066A (ja) * 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
AU2002328429A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
JP5253325B2 (ja) * 2002-09-04 2013-07-31 中外製薬株式会社 ＭＲＬ／ｌｐｒマウスを用いた抗体の作製
CA2644855C (en) 2006-03-09 2019-11-19 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
AU2007341631B9 (en) 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
PT2231708E (pt) * 2007-12-12 2015-07-30 Pincell Srl Remédios para pênfigo contendo anticorpos anti-ligando de faz
WO2010006772A2 (en) * 2008-07-14 2010-01-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
EP2166358A1 (de) * 2008-09-17 2010-03-24 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Differentialdiagnostisches Biomarker von einen Schlaganfall imitierenden Bedingungen und Verfahren zur Verwendung dieser
PT2376536E (pt) 2008-12-12 2015-05-11 Pincell Srl Remédios para pênfigo contendo anticorpos anti-ligando de faz
EP3076179A1 (de) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnose und behandlung von minderwertigen glioma
JP6884785B2 (ja) * 2015-09-23 2021-06-09 アポジェニックス アーゲー 抗ｃｄ９５ｌ抗体
CN113402601A (zh) * 2021-06-09 2021-09-17 河南中泽生物工程有限公司 一种抗非洲猪瘟病毒p54蛋白单克隆抗体的制备方法及应用
WO2023099578A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing anti-cd95l monoclonal antibodies
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950588A (en) * 1985-07-10 1990-08-21 Molecular Diagnostics, Inc. Prolonged enhanced chemiluminescence
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JPH09508009A (ja) 1994-01-07 1997-08-19 イミュネックス・コーポレーション Ｆａｓ抗原を結合するリガンド
DE4447484C2 (de) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose

Also Published As

Publication number Publication date
US6946255B1 (en) 2005-09-20
EP0872488A1 (de) 1998-10-21
AU716731B2 (en) 2000-03-02
EP0872488A4 (de) 1999-05-19
DE69636170D1 (de) 2006-06-29
JP3451092B2 (ja) 2003-09-29
EP0872488B1 (de) 2006-05-24
CA2215905A1 (en) 1996-09-26
DE69636170T2 (de) 2006-11-02
AU5014196A (en) 1996-10-08
WO1996029350A1 (fr) 1996-09-26

Similar Documents

Publication Publication Date Title
ATE327258T1 (de) Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
DE3788058D1 (de) Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
EP0842948A4 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
SE8006424L (sv) Sett att bestemma ett antigen i losning
BR8003501A (pt) Aperfeicoamento no processo de determinacao de um antigeno, anticorpo ou complexo ou conjugado de antigeno-anticorpo, e um conjunto de reagentes para determinacao de reacao de aglutinacao imunoquimica
DE59409947D1 (de) Verringerung des Hook-Effekts in Immuntests mit teilchenförmigem Trägermaterial
NZ329314A (en) Hybridoma & method of preparing a monoclonal antibody reactive with hc gp-39, use & treatment of rheumatoid arthritis
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
DE3480494D1 (en) Method and reagent for use in the assay of pivka-ii
CA2089395A1 (en) Monoclonal antibodies for detecting water treatment polymers
DE3580538D1 (de) Monoklonaler antikoerper, verfahren zu seiner herstellung, den monoklonalen antikoerper enthaltendes reagenz zum nachweiss eines krebsantigens und verfahren zu seiner herstellung.
ATE462975T1 (de) Verfahren zum immunochemischen testen des anti- hm1.24-antikörpers
FI955894A (fi) N-peptidin sandwich-tyyppinen immunomääritysmenetelmä
DE69332637T2 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
ATE174688T1 (de) Verfahren zur bestimmung von antigenen oder antikörpern in gegenwart eines immunkomplexes
EP0922761A4 (de) Monoklonaler antikörper, spezifisch für anti-humanes fibrinmonomer, verfahren zur herstellung desselben, hybrydomzellen und ein immunoassay-verfahren
AR243932A1 (es) Hibridoma, procedimiento para la preparacion, anticuerpo monoclonal, procedimiento para su preparacion y composicion para diagnostico de base a dicho anticuerpo.
NO873154L (no) Spesifikke monoklonale antistoffer mot overflatereseptor for ige og hybridcellelinjer som produserer disse antistoffer og anvendelse derav.
EP0629857A3 (de) Immunoassay zur quantitativen Bestimmung von Antigenen.
FR2710068B1 (fr) Dérivés de nucléosides, procédés de fabrication de ces dérivés de nucléosides et anticorps polyclonaux et monoclonaux spécifiques de ces dérivés.
DE69201463T2 (de) Diagnostisches Verfahren.
SE9502765D0 (sv) Analysförfarande
HK1008231A1 (en) Anti-tpo monoclonal antibody.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties